Fenimore Christopher R.'s most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 6,283 Common Stock done at an average price of $381.9 . Disclosure was reported to the exchange on Aug. 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | Christopher R. Fenimore | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 381.92 per share. | 18 Aug 2026 | 6,283 | 24,583 (0%) | 0% | 381.9 | 2,399,603 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | EVP Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2026 | 6,283 | 6,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 813.47 per share. | 18 Aug 2026 | 4,599 | 19,984 (0%) | 0% | 813.5 | 3,741,149 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | EVP Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2025 | 14,924 | 14,924 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | EVP Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2025 | 3,027 | 19,292 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Christopher R. Fenimore | EVP Finance CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 712.94 per share. | 05 Dec 2025 | 992 | 18,300 (0%) | 0% | 712.9 | 707,236 | Common Stock |
| Regeneron Pharma | R. Fenimore Christopher | SVP Finance & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 730.81 per share. | 16 Dec 2024 | 491 | 16,265 (0%) | 0% | 730.8 | 358,828 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2024 | 9,979 | 9,979 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2024 | 2,591 | 17,896 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 787.00 per share. | 06 Dec 2024 | 1,140 | 16,756 (0%) | 0% | 787 | 897,180 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1204.71 per share. | 28 Aug 2024 | 2,237 | 1,378 (0%) | 0% | 1204.7 | 2,694,936 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1205.49 per share. | 28 Aug 2024 | 928 | 450 (0%) | 0% | 1205.5 | 1,118,695 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1205.44 per share. | 28 Aug 2024 | 766 | 200 (0%) | 0% | 1205.4 | 923,367 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1206.15 per share. | 28 Aug 2024 | 450 | 0 (0%) | 0% | 1206.2 | 542,768 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1205.67 per share. | 28 Aug 2024 | 236 | 225 (0%) | 0% | 1205.7 | 284,538 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1205.67 per share. | 28 Aug 2024 | 235 | 225 (0%) | 0% | 1205.7 | 283,332 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1204.79 per share. | 28 Aug 2024 | 228 | 966 (0%) | 0% | 1204.8 | 274,692 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1206.67 per share. | 28 Aug 2024 | 200 | 25 (0%) | 0% | 1206.7 | 241,334 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1206.70 per share. | 28 Aug 2024 | 200 | 25 (0%) | 0% | 1206.7 | 241,340 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 1206.30 per share. | 28 Aug 2024 | 200 | 0 (0%) | 0% | 1206.3 | 241,260 | Common Stock |
| Regeneron Pharma | R. Christopher Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 953.47 per share. | 09 Feb 2024 | 1,342 | 16,072 (0%) | 0% | 953.5 | 1,279,557 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 954.57 per share. | 09 Feb 2024 | 1,100 | 14,972 (0%) | 0% | 954.6 | 1,050,027 | Common Stock |
| Regeneron Pharma | Fenimore Christopher R. | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 952.62 per share. | 09 Feb 2024 | 1,046 | 17,414 (0%) | 0% | 952.6 | 996,441 | Common Stock |
| Regeneron Pharma | Fenimore Christopher R. | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 955.00 per share. | 09 Feb 2024 | 600 | 14,372 (0%) | 0% | 955 | 573,000 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 951.39 per share. | 09 Feb 2024 | 487 | 18,460 (0%) | 0% | 951.4 | 463,327 | Common Stock |
| Regeneron Pharma | Fenimore Christopher R. | SVP Finance & CFO | Sale of securities on an exchange or to another person at price $ 950.49 per share. | 09 Feb 2024 | 344 | 18,947 (0%) | 0% | 950.5 | 326,969 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 555.67 per share. | 23 Jan 2024 | 5,000 | 21,860 (0%) | 0% | 555.7 | 2,778,350 | Common Stock |
| Regeneron Pharma | Fenimore Christopher R. | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 5,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | R. Christopher Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 5,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Fenimore Christopher R. | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 399.66 per share. | 23 Jan 2024 | 5,000 | 22,874 (0%) | 0% | 399.7 | 1,998,300 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 948.50 per share. | 23 Jan 2024 | 3,986 | 17,874 (0%) | 0% | 948.5 | 3,780,721 | Common Stock |
| Regeneron Pharma | R. Fenimore Christopher | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 948.50 per share. | 23 Jan 2024 | 3,583 | 19,291 (0%) | 0% | 948.5 | 3,398,476 | Common Stock |
| Regeneron Pharma | Christopher Fenimore R. | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 5,000 | 5,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 5,000 | 5,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher Fenimore R. | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 399.66 per share. | 03 Jan 2024 | 5,000 | 20,329 (0%) | 0% | 399.7 | 1,998,300 | Common Stock |
| Regeneron Pharma | R. Christopher Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 555.67 per share. | 03 Jan 2024 | 5,000 | 19,372 (0%) | 0% | 555.7 | 2,778,350 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 912.30 per share. | 03 Jan 2024 | 4,043 | 15,329 (0%) | 0% | 912.3 | 3,688,429 | Common Stock |
| Regeneron Pharma | R. Fenimore Christopher | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 912.30 per share. | 03 Jan 2024 | 3,469 | 16,860 (0%) | 0% | 912.3 | 3,164,769 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Sale of securities on an exchange or to another person at price $ 856.71 per share. | 27 Dec 2023 | 2,448 | 14,372 (0%) | 0% | 856.7 | 2,097,226 | Common Stock |
| Regeneron Pharma | Fenimore Christopher R. | SVP Controller | Sale of securities on an exchange or to another person at price $ 844.09 per share. | 21 Dec 2023 | 1,224 | 17,070 (0%) | 0% | 844.1 | 1,033,166 | Common Stock |
| Regeneron Pharma | R. Christopher Fenimore | SVP Controller | Sale of securities on an exchange or to another person at price $ 843.79 per share. | 21 Dec 2023 | 456 | 18,294 (0%) | 0% | 843.8 | 384,768 | Common Stock |
| Regeneron Pharma | R. Christopher Fenimore | SVP Controller | Sale of securities on an exchange or to another person at price $ 846.27 per share. | 21 Dec 2023 | 250 | 16,820 (0%) | 0% | 846.3 | 211,568 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 856.71 per share. | 12 Dec 2023 | 2,552 | 18,750 (0%) | 0% | 856.7 | 2,186,324 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 8,499 | 8,499 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher Fenimore R. | SVP Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 2,370 | 22,838 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Fenimore Christopher R. | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 844.09 per share. | 08 Dec 2023 | 1,276 | 21,562 (0%) | 0% | 844.1 | 1,077,059 | Common Stock |
| Regeneron Pharma | Fenimore R. Christopher | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 843.79 per share. | 08 Dec 2023 | 474 | 20,468 (0%) | 0% | 843.8 | 399,956 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 844.09 per share. | 08 Dec 2023 | 260 | 21,302 (0%) | 0% | 844.1 | 219,463 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2023 | 7,000 | 10,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 399.66 per share. | 23 Aug 2023 | 7,000 | 26,140 (0%) | 0% | 399.7 | 2,797,620 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 842.66 per share. | 23 Aug 2023 | 5,198 | 20,942 (0%) | 0% | 842.7 | 4,380,147 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Sale of securities on an exchange or to another person at price $ 806.47 per share. | 23 Mar 2023 | 2,192 | 18,409 (0%) | 0% | 806.5 | 1,767,782 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 5,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 270.43 per share. | 03 Feb 2023 | 5,000 | 23,581 (0%) | 0% | 270.4 | 1,352,150 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 774.29 per share. | 03 Feb 2023 | 3,286 | 20,295 (0%) | 0% | 774.3 | 2,544,317 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 7,111 | 7,111 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 1,926 | 18,581 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2022 | 871 | 0 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2022 | 436 | 461 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2022 | 435 | 460 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 753.28 per share. | 09 Dec 2022 | 247 | 16,655 (0%) | 0% | 753.3 | 186,060 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Sale of securities on an exchange or to another person at price $ 749.00 per share. | 05 Oct 2022 | 1,844 | 16,425 (0%) | 0% | 749 | 1,381,156 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Sale of securities on an exchange or to another person at price $ 724.00 per share. | 03 Oct 2022 | 3,346 | 18,269 (0%) | 0% | 724 | 2,422,504 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 5,000 | 5,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 270.43 per share. | 08 Apr 2022 | 5,000 | 30,066 (0%) | 0% | 270.4 | 1,352,150 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 736.21 per share. | 08 Apr 2022 | 3,451 | 26,615 (0%) | 0% | 736.2 | 2,540,661 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 2,450 | 10,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 555.67 per share. | 08 Apr 2022 | 2,450 | 27,221 (0%) | 0% | 555.7 | 1,361,392 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 736.21 per share. | 08 Apr 2022 | 2,155 | 25,066 (0%) | 0% | 736.2 | 1,586,533 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 270.43 per share. | 31 Mar 2022 | 10,000 | 31,628 (0%) | 0% | 270.4 | 2,704,300 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 700.99 per share. | 31 Mar 2022 | 6,857 | 24,771 (0%) | 0% | 701.0 | 4,806,688 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 555.67 per share. | 31 Mar 2022 | 2,000 | 23,425 (0%) | 0% | 555.7 | 1,111,340 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,000 | 12,450 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 700.99 per share. | 31 Mar 2022 | 1,797 | 21,628 (0%) | 0% | 701.0 | 1,259,679 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 664.34 per share. | 11 Dec 2021 | 270 | 21,122 (0%) | 0% | 664.3 | 179,372 | Common Stock |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 7,941 | 7,941 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Christopher R. Fenimore | SVP Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 1,859 | 21,392 (0%) | 0% | 0 | Common Stock |